Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan 1;9(3):479-487.
doi: 10.7150/jca.22157. eCollection 2018.

Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center

Yang Lv  1 , Cheng Huang  2 , Haizhou Xu  3 , Xu Han  1 , Lei Zhang  1 , Weilin Mao  1 , Yuan Ji  4 , Dayong Jin  1 , Wenhui Lou  1 , Xuefeng Xu  1
Affiliations

Clinicopathological Characteristics of the primary and metastatic Hepatic Neuroendocrine Tumors and the relevant Prognosis-Related Factors: A Retrospective Study of 81 Cases in a Single Chinese Center

Yang Lv et al. J Cancer. .

Abstract

Aims: We aim to describe the clinicopathological characteristics of hepatic neuroendocrine tumors (HNETs) and evaluate the relevant prognosis-related factors. Methods: The clinical data of 81 consecutive patients with primary or metastatic HNETs from March 2000 to July 2014 were retrospectively analyzed. Results: The mean (SD) age was 59.68 (11.64) years, 69.15% were men. The percentages of Grade G1, G2 and G3 tumors were 4.94%, 25.93% and 69.13%, respectively. Thirty-five cases were primary HNETs. Primary HNETs were more common in patients with larger tumors, lymph nodes invasions, tumor necrosis and portal vein tumor thrombus. The 1-, 3-, and 5-year overall survival rate were 88.89%, 32.10%, and 8.64%, separately. The relapse rate was 81.48% (66/81) and the mean (SD) relapse time was 18.79 (10.99) months. Reduced survival rate was associated with lymph node metastases (P=0.034), tumor necrosis (P=0.048), hard texture of tumor character (P=0.001), multifocality of tumor numbers (P=0.043), and the immunohistochemical expression of NSE (P=0.000) and Syn (P=0.037). Patients with metastatic HNETs were demonstrated with a more decreased period of Progression-free Survival (PFS) and Overall survival (OS) than their primary HNETs counterparts (P<0.05). Conclusion: Primary HNETs cohort patients were more common with aggressive clinical presentation. The hard texture of tumor character, multifocality of tumor numbers, and the immunohistochemical expression of NSE and Syn were independent predictive factors. Patients who were pathologically diagnosed as the primary HNETs seemed to achieve a long-term survival.

Keywords: clinicopathological characteristics; hepatic neuroendocrine tumors; prognosis..

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interest exists.

Figures

Figure 1
Figure 1
Representative case of Primary hepatic neuroendocrine tumors (PHNETs). Histopathological features of the PHNETs. (1) The hematoxylin-eosin staining of the PHNETs (×10); (2) the positive expression of chromogranin A in PHNETs (×20); (3) the positive expression of Hepa- in PHNETs (×20); (4) the positive expression of Syn in PHNETs (×20).
Figure 2
Figure 2
The comparison of PFS and OS between different treatment strategies.
Figure 3
Figure 3
The comparison of PFS and OS between different HNETs groups from the initial diagnosis. HNETs, Hepatic neuroendocrine tumors; OS, overall survival; PFS, progression-free survival.
See this image and copyright information in PMC

References

    1. Delle Fave G, Kwekkeboom DJ, Van Cutsem E. et al. Enets consensus guidelines for the management of patients with gastroduodenal neoplasms [J] Neuroendocrinology. 2012;95(2):74–87. - PubMed
    1. Pavel M, Baudin E, Couvelard A. et al. Enets consensus guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary [J] Neuroendocrinology. 2012;95(2):157–176. - PubMed
    1. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G. et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (gep-nets): Results from the national cancer registry of spain (rgetne) [J] Ann Oncol. 2010;21(9):1794–1803. - PubMed
    1. Lepage C, Bouvier AM, Phelip JM. et al. Incidence and management of malignant digestive endocrine tumours in a well defined french population [J] Gut. 2004;53(4):549–553. - PMC - PubMed
    1. Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors [J] Cancer. 1997;79(4):813–829. - PubMed